Table 3

Sensitivity analyses of persons without further autoimmune disease and with antimalarial therapy required

Persons with incident SLE in 2016 and without further autoimmune disease (n=453)Persons with incident SLE in 2016 and with antimalarial therapy (n=307)
20152016201720182015201620172018
Comorbidity diagnoses
 Elixhauser score, mean1.04.14.34.41.24.04.04.2
 Hypertension14.846.849.250.616.941.044.345.3
 Hyperlipidaemia7.325.826.526.76.820.220.220.2
 Cerebrovascular disease2.28.89.710.61.67.29.411.1
 Thrombosis0.73.33.14.00.74.65.24.9
 Kidney disease2.416.318.118.32.012.114.315.6
 COPD0.72.43.33.11.03.63.92.6
 Hypothyroidism6.017.017.018.35.514.015.015.6
 Osteoarthritis6.223.824.125.27.522.522.823.5
 Osteoporosis3.319.019.220.83.616.917.618.9
 Fibromyalgia1.56.06.05.72.36.26.55.9
 Depression12.430.231.832.513.430.931.332.9
 Polyneuropathy1.86.68.29.10.00.71.01.0
 Solid tumour1.86.87.37.92.36.86.87.2
 Metastatic cancer0.40.71.31.30.30.30.70.0
Specialist care
 Nephrologist11213142121213
 Neurologist310884989
 Psychiatrist14443444
Diagnostics
 Lipid profile1960575721575656
Hospitalisation1321393414274036
Drug prescriptions
 Mean number of drugs3.34.49.49.43.65.09.49.3
 Cardiovascular therapy*15.519.257.858.116.621.553.454.1
 Lipid-lowering drugs4.96.820.823.04.65.913.416.3
 Osteoporosis therapy1.82.28.47.92.02.610.110.4
 Antidepressants7.78.421.019.28.17.517.617.3
 NSAID14.619.036.636.919.524.435.237.8
 Other analgesics10.811.030.930.710.713.729.025.1
 Opioids4.97.316.116.14.67.213.014.0
  • *Antihypertensives, beta-blockers and/or diuretics.

  • COPD, chronic obstructive pulmonary disease; NSAID, non-steroidal antirheumatic drug.